Cargando…

Natural Killer T-Cell Agonist α-Galactosylceramide and PD-1 Blockade Synergize to Reduce Tumor Development in a Preclinical Model of Colon Cancer

Murine and human invariant natural killer T (iNKT) lymphocytes are activated by α-galactosylceramide (α-GalCer) presented on CD1d. α-GalCer was first described as a lipid that had strong anti-metastatic effects in a mouse melanoma model, and it has subsequently been shown to induce efficient iNKT ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Ying, Bhave, Madhura S., Yagita, Hideo, Cardell, Susanna L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606378/ https://www.ncbi.nlm.nih.gov/pubmed/33193386 http://dx.doi.org/10.3389/fimmu.2020.581301

Ejemplares similares

Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α-Galactosylceramide-Stimulated Natural Killer T Cells
por: Lee, Sung Won, et al.
Publicado: (2013)

Natural Killer T Cell Ligand α-Galactosylceramide Enhances Protective Immunity Induced by Malaria Vaccines
por: Gonzalez-Aseguinolaza, Gloria, et al.
Publicado: (2002)

α‐galactosylceramide generates lung regulatory T cells through the activated natural killer T cells in mice
por: Chen, Qianhui, et al.
Publicado: (2018)

Exogenous Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Reduces Pneumococcal Outgrowth and Dissemination Postinfluenza
por: Barthelemy, Adeline, et al.
Publicado: (2016)

CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Natural Killer T Cell Ligand α‐Galactosylceramide Inhibited Lymph Node Metastasis of Highly Metastatic Melanoma Cells
por: Nakui, Minoru, et al.
Publicado: (1999)

Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
por: King, Lisa A., et al.
Publicado: (2018)

Combination of the toll like receptor agonist and α-Galactosylceramide as an efficient adjuvant for cancer vaccine
por: Gableh, Fateme, et al.
Publicado: (2016)

CD1d-mediated Recognition of an α-Galactosylceramide by Natural Killer T Cells Is Highly Conserved through Mammalian Evolution
por: Brossay, Laurent, et al.
Publicado: (1998)

Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
por: Croudace, Joanne E, et al.
Publicado: (2008)

Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide
por: Schmieg, John, et al.
Publicado: (2003)

α-galactosylceramide-stimulated invariant natural killer T-cells play a protective role in murine vulvovaginal candidiasis by Candida albicans
por: Abe, Masahiro, et al.
Publicado: (2021)

Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15
por: Hsu, Chien-Ya, et al.
Publicado: (2021)

Activation of Invariant Natural Killer T Cells by α-Galactosylceramide Attenuates the Development of Angiotensin II-Mediated Abdominal Aortic Aneurysm in Obese ob/ob Mice
por: Saito, Akimichi, et al.
Publicado: (2021)

α-Galactosylceramide Analogs with Weak Agonist Activity for Human iNKT Cells Define New Candidate Anti-Inflammatory Agents
por: Bricard, Gabriel, et al.
Publicado: (2010)

Preclinical to clinical translation of anti-PD-1 blockade
por: Hirsch, Heather, et al.
Publicado: (2015)

Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment
por: Blake, Stephen J. P., et al.
Publicado: (2015)

The Yin and Yang of Invariant Natural Killer T Cells in Tumor Immunity—Suppression of Tumor Immunity in the Intestine
por: Wang, Ying, et al.
Publicado: (2018)

Intra-Peritoneal Hyperthermia Combining α-Galactosylceramide in the Treatment of Ovarian Cancer
por: Wu, Chao-Chih, et al.
Publicado: (2013)

Production of α-Galactosylceramide by a Prominent Member of the Human Gut Microbiota
por: Wieland Brown, Laura C., et al.
Publicado: (2013)

Evaluating α-galactosylceramide as an adjuvant for live attenuated influenza vaccines in pigs
por: Artiaga, Bianca L., et al.
Publicado: (2022)

Efficient synthesis of α-galactosylceramide and its C-6 modified analogs
por: Li, Huiting, et al.
Publicado: (2022)

Characterization of a Glycolipid Synthase Producing α-Galactosylceramide in Bacteroides fragilis
por: Caballé, Marc, et al.
Publicado: (2022)

Enhancement of Mucosal Immunogenicity of Viral Vectored Vaccines by the NKT Cell Agonist Alpha-Galactosylceramide as Adjuvant
por: Singh, Shailbala, et al.
Publicado: (2014)

Defining a novel subset of CD1d‐dependent type II natural killer T cells using natural killer cell‐associated markers
por: Singh, Avadhesh Kumar, et al.
Publicado: (2019)

Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d
por: Clark, Katharine, et al.
Publicado: (2019)

Prophylactic Sublingual Immunization with Mycobacterium tuberculosis Subunit Vaccine Incorporating the Natural Killer T Cell Agonist Alpha-Galactosylceramide Enhances Protective Immunity to Limit Pulmonary and Extra-Pulmonary Bacterial Burden in Mice
por: Khan, Arshad, et al.
Publicado: (2017)

PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
por: Koerner, Julia, et al.
Publicado: (2021)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
por: Liu, Peng, et al.
Publicado: (2022)

Toll-like Receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes
por: Ando, Tatsuya, et al.
Publicado: (2013)

Efficient Divergent Synthesis of New Immunostimulant 4″-Modified α-Galactosylceramide Analogues
por: Janssens, Jonas, et al.
Publicado: (2017)

Synthesis and Immunological Activity of Novel Oligo(ethylene glycol) Analogues of α-Galactosylceramide
por: Pawar, Mithun S., et al.
Publicado: (2022)

PD-1 Immune Checkpoint Blockade and PSGL-1 Inhibition Synergize to Reinvigorate Exhausted T Cells
por: Viramontes, Karla M., et al.
Publicado: (2022)

Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells
por: Akutsu, Yasunori, et al.
Publicado: (2002)

PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells
por: Guo, Yanan, et al.
Publicado: (2016)

TNFα-blockade stabilizes local airway hyperresponsiveness during TLR-induced exacerbations in murine model of asthma
por: Starkhammar, Magnus, et al.
Publicado: (2015)

The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells
por: Kitamura, Hidemitsu, et al.
Publicado: (1999)

Sunitinib Exerts In Vitro Immunomodulatory Activity on Sarcomas via Dendritic Cells and Synergizes With PD-1 Blockade
por: Ocadlikova, Darina, et al.
Publicado: (2021)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_of41uoe1e1g1ul6vds83gcctk8